Abstract
INTRODUCTION Adverse events (AE) such as pain at injection site or fever are common after COVID-19 vaccination. We aimed to describe determinants of AE after COVID-19 vaccination and investigate the association between AE and pre- and post-vaccination antibody concentrations.
METHODS Participants of an ongoing prospective cohort study (VASCO) completed a questionnaire on AE within two months after COVID-19 vaccination and provided 6-monthly serum samples. Data from May 2021 to November 2022 were included. Logistic regression analyses were performed to investigate determinants of AE after mRNA vaccination, including pre-vaccination Ig antibody concentrations against the receptor binding domain. Multivariable linear regression was performed in SARS-CoV-2 naïve participants to assess the association between AE and log-transformed antibody concentrations 3-8 weeks after mRNA vaccination.
RESULTS 47,947 AE questionnaires were completed by 28,032 participants. In 42% and 34% of questionnaires, injection site and systemic AE were reported, respectively. In 2.2% of questionnaires, participants sought medical attention due to AE. AE were reported significantly more frequently by women, younger participants (<60 years), participants with medical risk conditions and Spikevax recipients (versus Comirnaty). Higher pre-vaccination antibody concentrations were associated with higher incidence of systemic AE after the second and third dose, but not with injection site AE or AE for which medical attention was sought. Any AE after the third dose was associated with higher post-vaccination antibody concentrations (geometric mean concentration ratio: 1.38, 95%CI 1.23-1.54).
CONCLUSION Our study suggests that high pre-vaccination antibody levels are associated with AE, and that experiencing AE may be a marker for a good antibody response to vaccination.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
https://trialsearch.who.int/Trial2.aspx?TrialID=NL9279
Funding Statement
This study was funded by the Dutch Ministry of Health, Welfare and Sport
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The VASCO study protocol was approved by the Medical Ethics Committee of Stichting Beoordeling Ethiek Biomedisch Onderzoek (BEBO), Assen, the Netherlands
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Ethical statement: The VASCO study protocol was approved by the Medical Ethics Committee of Stichting Beoordeling Ethiek Biomedisch Onderzoek (BEBO), Assen, the Netherlands. The VASCO study is conducted according to the principles of the Declaration of Helsinki. Written informed consent was obtained from all participants.
Funding statement: This study is funded by the Dutch ministry of Health, Welfare and Sport.
Data availability: All data produced in the present study are available in aggregated and anonymized form upon reasonable request to the authors.
Conflict of interest: None
Data Availability
All data produced in the present study are available in aggregated and anonymized form upon reasonable request to the authors.
